Bayer said on Tuesday that its Monsanto chemical subsidiary has proposed a $7.25 billion settlement to resolve lawsuits by customers alleging that its Roundup weedkiller product caused non-Hodgkin ...

A professional hairstylist and mother of two was diagnosed with a rare form of lymphoma. She involved her 5-year-old son in shaving her head to help him process her changing appearance. Aleksandra ...

Inflammatory bowel disease (IBD) is an umbrella term for a group of chronic conditions that cause inflammation and swelling in the digestive tract. It primarily includes two conditions: ulcerative ...

We’re all just living our lives at the mercy of the almighty algorithm—and if you’re as beauty obsessed as we are, you’ve likely stumbled upon those lymphatic face brushes on TikTok or Instagram. It’s ...

A team of University of South Florida investigators led by Jerome Breslin, professor of Molecular Pharmacology and Physiology in the USF Health Morsani College of Medicine, has received $3.3 million ...

A team of USF Health investigators led by Jerome Breslin, PhD, has received a $3.3 million federal award to fund an innovative program that may shed significant light in identifying the role ...

Hodgkin’s lymphoma is definitively diagnosed by the presence of Reed-Sternberg cells, whereas Non-Hodgkin’s lymphoma involves a wider range of lymphoid variations and is classified based on cell ...

BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of ...

Lymphatic drainage is 2025’s biggest wellness trend. Shop top-rated tools that de-puff, sculpt, and tone—starting at only $10. "I wasn't sure what to expect from dry-brushing. I'm newly diagnosed with ...

In November, 26-year-old Hardee Bhavsar crossed a big item off her bucket list: running the New York City Marathon. It was her first marathon, which is something she never imagined she'd be able to ...

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with =3 prior lines of therapy, with no new safety signals emerging over time.